5%利多卡因凝胶贴膏治疗带状疱疹后神经痛研究进展

RESEARCH PROGRESS IN THE TREATMENT OF POST-HERPETIC NEURALGIA WITH 5% LIDOCAINE MEDICATED PALASTERABULA Nuerbiya,YANG Xu,LYU Liang-Liang,WANG Wen,YANG Yang,FAN Bi-Fa

摘要:

带状疱疹后神经痛(Post-herpetic neuralgia，PHN)是一种严重影响老年人的慢性疼痛综合征，它的发病率预计会随着人口老龄化而增加。5%利多卡因凝胶贴膏（Lidocaine medicated plasters，LMP)是治疗PHN的首选药物。本文综述了5%LMP治疗PHN的临床药理学研究、总结了有效性、安全性和耐受性相关临床数据，旨在证实5%LMP对PHN患者的有效性和安全性。根据已公开的研究数据，在PHN治疗中，5%LMP与普瑞巴林疗效相似，但耐受性更优，5%LMP在PHN患者中的优势在于较少的药物相关不良事件和治疗中断相关事件的发生。5%LMP联合全身性药物治疗使镇痛效果显著增加，副作用减少，进一步证明了多模式镇痛在PHN中的价值。5%LMP在长期使用后仍有持续的治疗疗效，同时在其他类型的局限性神经病理性疼痛（Localized neuropathic pain，LNP）中也体现了良好的镇痛疗效。轻度的局部反应是5%LMP相关最常见的不良事件， 5%LMP系统性不良事件的发生和药物相互作用风险极小。虽然有必要进行进一步的随机对照临床研究，但5%LMP在PHN长期管理中是安全有效的，而且由于其不良事件发生率低，对老年人和/或儿童可能有特殊的临床效益。

Abstract:

Post-herpetic neuralgia (Post-herpetic neuralgia, PHN) is a chronic pain syndrome that seriously affects the elderly, and its incidence is expected to increase with the aging of the population. 5% Lidocaine medicated plaster (Lidocaine medicated plasters, LMP) is the first choice for the treatment of PHN. This article reviews the clinical pharmacological studies of 5%LMP for PHN, and summarizes the clinical data related to the efficacy, safety and tolerability of 5%LMP in order to confirm the efficacy and safety of 5%LMP in patients with PHN. According to the published research data, the efficacy of 5%LMP is similar to that of pregabalin in PHN treatment, but it is more tolerable. The advantage of 5%LMP in PHN patients is that there are fewer drug-related adverse events and treatment disruption-related events. 5%LMP combined with systemic drugs can significantly increase the analgesic effect and reduce the side effects, which further proves the value of multimodal analgesia in PHN. 5%LMP still has a continuous therapeutic effect after long-term use, and it also shows a good analgesic effect in other types of localized neuropathic pain (Localized neuropathic pain, LNP). Mild local reactions are the most common adverse events associated with 5%LMP, while the risk of systemic adverse events and drug interactions in 5%LMP is minimal. Although further randomized controlled clinical trials are necessary, 5%LMP is safe and effective in the long-term management of PHN and may have special clinical benefits for the elderly and / or children because of its low incidence of adverse events.